ad image

Autologous

1 / 1
Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support
Cell Therapy

Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support

Sarah Meeks, Ph.D.

MaxCyte

PAO-09-23-CL-09Sep 28, 2023
A Novel Technology Platform for Bone Regeneration and Cancer Treatment
Bone Regeneration

A Novel Technology Platform for Bone Regeneration and Cancer Treatment

Denis Dufrane, M.D., Ph.D.

PAO-03-23-CL-06Mar 20, 2023
Terumo Blood and Cell Technologies
T Cell Expansion Platform

Terumo Blood and Cell Technologies Presents First Quantum® Flex Data for Multiple Size Bioreactors Showing Rapid T Cell Expansion to Numbers Equivalent of a Therapeutic Dose

Terumo Blood and Cell Technologies

PR-M02-23-03Feb 23, 2023
Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles
Cell Therapy

Moving from Autologous to Allogeneic Cell Therapies: Drivers and Hurdles

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-01-23-NI-01Jan 31, 2023
Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality
Cell Therapy

Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-NI-08Nov 15, 2022
A PODular Therapies-as-a-Service Approach To Fundamentally Change the CAR-T Cell Therapy Landscape
Cell Therapy

A PODular Therapies-as-a-Service Approach To Fundamentally Change the CAR-T Cell Therapy Landscape

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-022-CL-05May 31, 2022
Anixa Biosciences
Phase I Trial

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase I Trial at Moffitt Cancer Center

Anixa Biosciences

PR-M03-22-17Mar 30, 2022
Expanding Access to Cell Therapies with a Patient-Centric Focus
Cell Therapy

Expanding Access to Cell Therapies with a Patient-Centric Focus

Amy L. Ronneberg

Be The Match BioTherapies

PAO-02-022-CL-12Mar 12, 2022
Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure
Cell Therapy

Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure

Chris McClain

Be The Match BioTherapies

PAO-09-21-CL-04Sep 09, 2021
Economically Viable, Same-Day Autologous Cell Therapies
Cell Therapy

Economically Viable, Same-Day Autologous Cell Therapies

Gregory Frost, Ph.D.; Sid Kerkar, M.D.

EXUMA Biotechnology

PAO-01-21-CL-06Feb 04, 2021
A Personalized Cell Therapy Chain Management Platform
Cell Therapies

A Personalized Cell Therapy Chain Management Platform

Matthew Lakelin

TrakCel

PAP-Q2-20-CL-032Jul 01, 2020
1 / 1